Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled
Jian Xie1, Mingyang Jiang2, Yunni Lin2
11 Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute, Nanning, Guangxi, China.
Insights
Alprostadil may help prevent contrast-induced nephropathy (CIN), a common cause of kidney injury. This meta-analysis showed a lower CIN incidence and improved kidney function markers in patients receiving alprostadil.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a significant cause of hospital-acquired acute kidney injury.
- Alprostadil's role in renal blood flow and electrolyte balance suggests potential for CIN prevention, though evidence is debated.
Purpose of the Study:
- To evaluate the efficacy of alprostadil in preventing CIN in patients undergoing contrast media procedures.
- To synthesize existing evidence through a meta-analysis of relevant studies.
Main Methods:
- A meta-analysis of 36 studies involving 5495 patients was conducted.
- Patients received standard hydration; the experimental group received alprostadil, while the control group did not.
- Renal function markers including serum creatinine, BUN, eGFR, cystatin C, CCr, and β2-MG were assessed post-contrast injection.
Main Results:
- The incidence of CIN was significantly lower in the alprostadil group (6.56%) compared to the control group (16.74%).
- Patients treated with alprostadil showed reduced levels of SCr, BUN, cystatin C, and β2-MG.
- Improved CCr and eGFR were observed in the experimental group.
Conclusions:
- Alprostadil administration appears to reduce the incidence of CIN.
- The findings suggest alprostadil is a potential therapeutic agent for preventing CIN in patients undergoing coronary angiography and/or PCI.
Abstract:
Contrast-induced nephropathy (CIN) is the third leading cause of acquired acute renal injury in hospitalized patients. Alprostadil plays a role in the maintenance and redistribution of intrarenal blood flow and the excretion of electrolytes and water. However, the effectiveness of alprostadil in preventing CIN remains controversial. Thirty-six articles with a total of 5495 patients were included in this study. Both groups (experimental group and control group) received standard hydration therapy. In the experimental group, patients received different doses of alprostadil. Serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), cystatin C, creatinine clearance rate (CCr), and β2-microglobulin (β2-MG) were measured at 24, 48, and 72 hours after contrast media injection. The incidence of CIN in the experimental group was significantly lower than that in the control group (6.56% vs 16.74%). The level of SCr, cystatin C, BUN, and β2-MG in the experimental group was lower than those in the control group; CCr and eGFR in the experimental group were higher than those in the control group. This study demonstrated that alprostadil may reduce the incidence of CIN in patients undergoing coronary angiogram and/or percutaneous coronary intervention.
Related Concept Videos
Statistical Software for Data Analysis and Clinical Trials
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Random Error
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...

